FREE ELECTRONIC LIBRARY - Dissertations, online materials

Pages:   || 2 |

«A. PURPOSE This document describes the Center for Devices and Radiological Health’s (CDRH’s, or Center’s) process to clarify and more quickly ...»

-- [ Page 1 ] --

Responsible Office/Division: Document Page 1 of 11

Office of the Center Director Number:


Process Owner: Version Number: Effective Date:

CDRH Associate Director for Policy 2.0 March 26, 2014

Center for Devices and Radiological Health

Standard Operating Procedure (SOP) Level 1, Immediately in Effect Guidance Documents on Premarket Data Issues


A. Purpose B. Background C. Premarket IIE Document Procedures D. Effective Date E. Appendices A. PURPOSE This document describes the Center for Devices and Radiological Health’s (CDRH’s, or Center’s) process to clarify and more quickly inform stakeholders when CDRH has changed its expectations relating to, or otherwise has new scientific information that could affect data submitted as part of an Investigational Device Exemption (IDE) or premarket submission, including a Premarket Notification (510(k)), a Premarket Approval (PMA), or a Humanitarian Device Exemption (HDE), including combination products containing a device constituent part for which CDRH has jurisdiction, that needs to be disseminated in a timely manner. Generally, the issues raised by new scientific information should be thoroughly considered with the benefit of input from other stakeholders who have expertise and viewpoints that may add appropriate balance, even when these outside-the agency viewpoints may differ. However, in some instances there are public health reasons for the immediate implementation of new premarket regulatory expectations that outweigh the need for pre-implementation feedback from affected stakeholders.

In these instances, CDRH will communicate through Level 1, Immediately in Effect (IIE) Guidance Documents using Good Guidance Practices (GGPs). As it does currently, the Center will publish a Federal Register document announcing the guidance, post the IIE guidance documents on its website, and may also contemporaneously issue other communications to affected industry stakeholders summarizing the information in the IIE guidance.

FDA’s guidance documents do not create or confer any rights for or on any person and does not operate to bind FDA or the public.

B. BACKROUND Currently, manufacturers typically learn of changes CDRH implements regarding what data or how to gather specific data in support of an IDE, 510(k), PMA, or HDE at the time of or soon Uncontrolled when printed For the current copy, check https://traction.fda.gov/traction#/dashboard&proj=CDRHSOP Title: SOPfor IIE Guidance on Premarket Document Number: CDRHOCD015 Page 2 of 11 Issues after a decision is made through individual engagement with the Center, often not until after they have prepared that submission. Reviewers may implement these changes, such as requesting new clinical data or using a new test method, on a case-by-case basis, with immediate supervisory concurrence when it is necessary to protect the public health. For example, a reviewer may request that sponsors test their implantable device for durability because new data demonstrates that this type of device is prone to failure due to premature wear and tear of the technology. Although CDRH may issue a detailed guidance document, the document may not publish until a year or more after a Branch- or a Division-level decision has been made to request the information because of the resource constraints in developing guidance documents.

Therefore, CDRH believes that timely communication with industry about changes in premarket regulatory expectations is important. FDA’s GGPs regulation provides a mechanism for communicating and implementing certain changes in regulatory expectations quickly, without requiring prior public comment. Under 21 CFR 10.115(g)(2), FDA may issue a IIE guidance when prior public participation is not “feasible or appropriate.” In the preamble to the final GGPs rule, FDA identified the following three examples in which IIE guidance could be appropriate because prior public comment may not be feasible or appropriate: 1) there are public health reasons for the immediate implementation of the guidance document; 2) there is a statutory requirement, executive order or court order that requires immediate implementation; or

3) the guidance document presents a less burdensome policy that is consistent with public health.

Under these circumstances, CDRH intends to use the procedures described in 21 CFR 10.115(g)(2) to issue guidance documents addressing changes in premarket regulatory expectations. CDRH would open a public docket upon issuance of the guidance through a Notice of Availability (NoA) in the Federal Register, and, subsequently, make changes to the guidance, if appropriate based on public comment. In certain circumstances, CDRH plans to contemporaneously issue letters to affected industry stakeholders summarizing the information in the IIE guidance. The IIE guidance documents will be posted on the FDA Web site. CDRH has developed this Standard Operating Procedure (SOP) to facilitate issuance of such guidance documents.

This SOP is being implemented after considering the comments on this topic.


STEP 1: Initiating development of a Premarket IIE Guidance

1.1 Initiating development of a Premarket IIE Guidance should be considered when the

following criteria are met:

a. New scientific information (e. g., product complaints/recalls or unique risks that are not previously identified such as a new failure mode identified during clinical use of the product) has been identified that raises a new, important safety risk or demonstrates that currently used test methods or clinical trial designs are inadequate to demonstrate safety, effectiveness, and/or substantial equivalence of a device type;

Title: SOP for IIE Guidance on Premarket Document Number: CDRHOCD015 Page 3 of 11 Issues

–  –  –

1.2 If the above criteria are met, then Office of Device Evaluation (ODE) or Office of In Vitro Diagnostics and Radiological Health (OIR) staff should present the identified issue to the appropriate Office-Level Management, including Office Director, following appropriate internal discussions with subject matter experts and Branch and/or Division management. Staff should also confirm that other CDRH Offices or FDA Centers are not implicated in any changes resulting from the new scientific information. Upon concurrence from the ODE or OIR Director, the process outlined below should be followed, instead of CDRH’s standard guidance development process.

STEP 2: Presentation to the Center Science Council

2.1 The appropriate staff and their management should consult with the Center Science Council (CSC). A briefing summary providing the following information should be presented and discussed (see Appendix 1 for the Premarket IIE Guidance Document

Center Science Council Briefing Summary):

–  –  –

1 Generally, previously cleared or approved submissions should be unaffected.

Title: SOP for IIE Guidance on Premarket Document Number: CDRHOCD015 Page 4 of 11 Issues new information must be communicated using either IIE Guidance Document or a draft guidance document using the traditional procedures for prior public participation. If the new information does not warrant a change in regulatory expectations, the CSC should determine whether a separate communication should be issued alerting stakeholders to new scientific information. Such communications are not addressed by this SOP.

· Whether new regulatory expectations should be communicated using IIE procedures or the standard procedures for guidance development.

If the Center is proposing a change in regulatory expectations, the CSC may provide a recommendation whether a traditional guidance document should be issued in draft and finalized, or whether the Center should issue a Premarket IIE Guidance Document under this SOP because, for example: a) there are public health reasons for the immediate implementation of the guidance document; b) there is a statutory requirement, executive order or court order that requires immediate implement; or c) the guidance document presents a less burdensome policy that is consistent with public health. The CSC’s recommendation will be reviewed by Senior CDRH leadership to ensure the CSC recommendations meet regulatory and legal standards, such as the regulatory standard for issuance of IIE guidance.

· Whether additional expertise on the topic is required before determining the appropriate response to the new information.

If so, the appropriate mechanisms should be followed to obtain external expertise.

STEP 3: Develop Premarket IIE Guidance Document

3.1 Once a decision has been made by the Center to issue a Premarket IIE Guidance, the guidance should be developed using Appendix 2 as a template.

3.2 The Premarket IIE Guidance should ideally be 1-2 pages, and generally no more than 5

pages in length. The Premarket IIE Guidance should:

a. Identify the appropriate audience (e.g., all manufacturers of a specific device type);

b. Identify the new scientific information and source of information that supports CDRH’s decision to issue a Premarket IIE Guidance;

c. Discuss why this new scientific information warrants a change in regulatory expectations for the device type or is of importance to the specified audience;

d. Explain why public comment prior to issuance is not feasible or appropriate such that a Premarket IIE Guidance Document is being issued;

e. Outline the changes in regulatory expectations, such as changes in data expected to be submitted in light of this new scientific information;

f. Explain why CDRH’s regulatory expectations are changing;

g. Identify whether such changes apply only to new IDEs or premarket submissions or also to IDEs or premarket submissions already under review at CDRH;

h. If such changes apply to premarket submissions already under review at CDRH, identify how the new issues may be considered by the sponsor, (e.g., phasing in changes, acceptance of alternative measures, or proposed dates for Title: SOP for IIE Guidance on Premarket Document Number: CDRHOCD015 Page 5 of 11 Issues

–  –  –

3.3 In addition, the Premarket IIE Guidance should reference any other communication or publicly available information from CDRH related to the issue discussed in the Premarket IIE Guidance.

STEP 4: Review and Clearance of the Premarket IIE Guidance Document

The Premarket IIE Guidance should be reviewed and cleared as follows:

4.1 The GGP Representative should review the IIE Guidance for GGP conformance and document quality. The GGP Representative will develop a NoA to be published in tandem with the posting of the Premarket IIE Guidance Document on the CDRH Web site.

4.2 The ODE or OIR Director or their designee should review and clear the Premarket IIE Guidance with respect to content and Office-level policy.

4.3 The CDRH Deputy Directors for Policy and Science should review and clear the Premarket IIE Guidance with respect to content and Center-level policy.

4.4 The Office of Chief Counsel (OCC) should review the Premarket IIE Guidance for legal sufficiency and accuracy.

4.5 The Center Director should provide final clearance of the Premarket IIE Guidance.

STEP 5: Issue Premarket IIE Guidance Document

Premarket IIE Guidances should be issued as follows:

5.1 Publish a NoA in the Federal Register announcing availability of the Premarket IIE Guidance and requesting comments.

5.2 Post a copy of the Premarket IIE Guidance on the CDRH Web site. All Premarket IIE Guidance will be posted in one readily accessible location.

5.3 Determine any other appropriate methods for distribution, such as email or postal mail.

5.4 If it would be appropriate to distribute additional communications on this topic, identify relevant stakeholders and determine the appropriate mechanism for distribution.

STEP 6: Review of Comments and Revision of Premarket IIE Guidance Comments submitted following issuance of a Premarket IIE Guidance should be reviewed by the appropriate staff to determine if revisions should be made to the document based on the comments.

6.1 Collect comments from the docket for 60 days after the Premarket IIE Guidance was published Title: SOP for IIE Guidance on Premarket Document Number: CDRHOCD015 Page 6 of 11 Issues

6.2 Review comments and determine if and how comments should be incorporated into the guidance. Administrative record of the comments and revisions will be maintained.

6.3 Recommendations should be presented to the CSC for discussion.

6.4 Revised guidance documents should be issued 90 days after the initial comment period closes, and will reference the previous version of the guidance.

6.5 If after reviewing the comments the Center decides no revisions are necessary, the publicly available version of the guidance should be updated to indicate all comments have been reviewed and no changes are being made. This update should occur 90 days after the initial comment period closes.

6.6 Publicly report number of Premarket IIE Guidance issued at periodic intervals.

Title: SOP for IIE Guidance on Premarket Document Number: CDRHOCD015 Page 7 of 11 Issues D. EFFECTIVE DATE This SOP is effective March 26, 2014.


–  –  –

Describe the device or device type and provide a brief regulatory history of the device or device type.

1. What new scientific information is available to CDRH regarding the device or device type?

2. How does this new scientific information change the risk/benefit profile of the device or device type?

3. What changes are expected in CDRH’s interpretation of or policy on a regulatory issue in light of this new scientific information?

4. Why are these changes or other communication necessary?

5. Who needs to be aware of the proposed changes or communication?

6. What submissions would be affected?

Please identify type of submissions (e.g., IDE, or PMA) and the status of the submissions (e.g., pending, or future).

Pages:   || 2 |

Similar works:

«Infectious Disease Epidemiology Section Office of Public Health, Louisiana Dept of Health & Hospitals 800-256-2748 (24 hr number) www.infectiousdisease.dhh.louisiana.gov HERPES B MONKEY VIRUS Revised 09/24/2009 Herpes B Monkey virus is now known as Cercopithecine herpes virus 1. It has also been known as monkey B virus, herpes B virus, B virus or Herpesvirus simiae. Virology B virus is an alpha herpes virus that infects members of the genus Macaca. Members of this genus include Old World...»

«Oxford Handbook of Clinical and Laboratory Investigation Drew Provan Andrew Krentz OXFORD UNIVERSITY PRESS OXFORD MEDICAL PUBLICATIONS Oxford Handbook of Clinical and Laboratory Investigation Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most upto-date published product information and data sheets provided by the manufacturers and...»

«CURRICULUM VITAE CHARLES A. DOWNS, PhD, ACNP-BC Assistant Professor Nell Hodgson Woodruff School of Nursing & Department of Physiology School of Medicine 1520 Clifton Road NE, Suite 238 Emory University Atlanta, GA 30322 Tel: (404) 727-6936 Fax: (404) 727-6936 Email: charles.downs@emory.edu EDUCATION Dates Degree Institution Major 2011-2012 Postdoctoral Emory University Physiology Fellow Atlanta, Georgia (Cellular & Molecular Physiology) 08/2011 PhD University of Arizona Nursing Tucson, Arizona...»

«Gary Reiter 1955Andy Kaplan Rob Malow 2003 1959-2006 1953-2013 (My) Turning Points in HIV Treatment Adherence Research David Bangsberg, MD, MPH Director Massachusetts General Hospital Center for Global Health Professor Harvard Medical School Professor Harvard School of Public Health Visiting Professor Mbarara University of Science and Technology My Turning Points • 1992 Missed the first ART adherence study for over 10 years • 1995 Back to basics • 1996 Hope and fear • 2000 95% or else...»

«INDEX Advice Guidance Signposting Finding a GP / Hospital / Dentist Page 4 Page 5 – 6 Dental Access Practices Community Dental Team Pages 7 8 Entitlement to Free Dental Treatment Page 9 -10 Finding Social Services Page 11 Page 12 – 13 Housing / Repairs/ Filling Forms / Socialising Benefits / Welfare reforms / Bedroom Tax Page 14 Page 15 – 17 Travel Vaccinations Gender Identity Clinics Page 18 Wheelchair Loans Page 19 1 Complaints Wolverhampton Health Advocacy Page 21 New Cross, West Park...»

«The 4 Week Beach Body by James Alexander-Ellis The 4 Week Beach Body Before I begin, let me state that I can't strongly recommend a crash diet as such. Anything offering dramatic or sudden weight loss in a short time isn't a long term solution, and generally I promote healthy and sustainable body composition changes. However. We live in a world of quick fixes, deadlines and frankly. The desire for fast results. Many of my 1-1 clients will often say to me something along the lines of so I really...»

«Are Cyanobacteria (“blue-green algae”) toxic? What are cyanobacteria (“blue-green algae”)? Cyanobacteria, often referred to as “blue-green algae,” are a group of microscopic bacteria that are photosynthetic (can make some of their own nutrients using energy from light). They can exist as single cells or groups of cells. Microcystis Lyngbya Microscope photo credit: Debbie Hunter, UC Davis Why do we need to know about cyanobacteria? Some species of cyanobacteria are capable of...»

«Health, Safety and Reclamation Code for Mines in British Columbia Ministry of Energy, Mines and Petroleum Resources Mining and Minerals Division Victoria, British Columbia 2008 Canadian Cataloguing in Publication Data Main entry under title: Select Standing Health, safety and reclamation code for mines in British Columbia 2008 reprinting of 2003 ed. Includes Index. ISBN 978-0-7726-6011-4 1. Mine safety — Law and legislation — British Columbia. 2. Mineral industries — Health aspects —...»

«Aus der Klinik für Augenheikunde Der Universität zu Lübeck Direktor: Prof. Dr. med. H. Laqua Development of a New Lubricant and Nutrient Tear Substitute Inauguraldissertation zur Erlangung der Doktorwürde Der Universität zu Lübeck Aus der Medizinischen Fakultät Vorgelegt von LIU Lei Aus Dandong Lübeck 2004 1. Berichterstatter:2. Berichterstatter:Tag der mündlichen Prüfung: Zum Druck genehmigt: Lübeck, den TABLE OF CONTENTS 1 INTRODUCTION 1.1 THE OCULAR SURFACE 1.1.1 Anatomy of the...»

«Center for Domestic and International Health Security A R A N D H E A LT H P R O GRAM This PDF document was made available from www.rand.org as a public THE ARTS service of the RAND Corporation. CHILD POLICY CIVIL JUSTICE EDUCATION Jump down to document6 ENERGY AND ENVIRONMENT HEALTH AND HEALTH CARE INTERNATIONAL AFFAIRS The RAND Corporation is a nonprofit research NATIONAL SECURITY organization providing objective analysis and effective POPULATION AND AGING solutions that address the...»

«Promoting stroke recovery using delayed growth factor delivery: Contribution of ipsilesional versus contralesional pyramidal tract plasticity Inaugural-Dissertation zur Erlangung des Doktorgrades Dr. rer. nat. Der Fakultät für Biologie an der Universität Duisburg-Essen vorgelegt von Raluca Reitmeir aus Rumänien Juni 2013 1. Gutachter: Prof. Dr. Dirk Hermann 2. Gutachter: Prof. Dr. Michael Ehrmann 3. Gutachter: Prof. Dr. Andrea Vorkamp Vorsitzender des Prüfungsausschusses: Prof. Dr. Ruth...»

«Good Practice Guidance and Uncertainty Management in National Greenhouse Gas Inventories CH4 EMISSIONS: COAL MINING AND HANDLING ACKNOWLEDGEM E N T This paper was written by William Irving (USEPA) and Oleg Tailakov (Russia Coalbed Methane Center). It was reviewed by Dina Kruger (USEPA) and David Williams (CSIRO).ABSTRACT The amount of methane (CH4 ) released during coal mining depends on a number of factors, the most important of which are coal rank, coal seam depth, and method of mining....»

<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.